Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANA598 + peginterferon + ribavirin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**ANA598 + peginterferon + ribavirin** is a triple combination regimen studied for the treatment of chronic hepatitis C virus (HCV) infection, specifically in genotype 1 patients. **ANA598 (setrobuvir)** is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase (NS5B), developed by Anadys Pharmaceuticals. In clinical studies, combining ANA598 with the standard-of-care therapy of pegylated interferon alfa and ribavirin showed increased antiviral activity and a favorable safety profile during the 12-week interim of Phase II trials. **Peginterferon** is an immunomodulatory cytokine that promotes antiviral effects, and **ribavirin** is a nucleoside analog with broad-spectrum antiviral properties. The ANA598 combination demonstrated a high rate of early virological response, but development was not continued to approval following these trials[1][3][5].
- Other names
- setrobuvir + peginterferon + ribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on ANA598 + peginterferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANA598 + peginterferon + ribavirin.